Quadruple therapy with vonoprazan 20 mg daily as a first‐line treatment for <i>Helicobacter pylori</i> infection: A single‐center, open‐label, noninferiority, randomized controlled trial-Reference-Cited by-同舟云学术

Quadruple therapy with vonoprazan 20 mg daily as a first‐line treatment for Helicobacter pylori infection: A single‐center, open‐label, noninferiority, randomized controlled trial

Published:2022-12 Issue:1 Volume:28 Page:
ISSN:1083-4389
Container-title:Helicobacter
language:en
Short-container-title:Helicobacter

Author:

Lu Lifen¹,Wang Yujing¹^ORCID,Ye Jun¹^ORCID,Han Yuehua¹,Lou Guochun¹,Li Yan¹,Yan Huihui¹^ORCID,Du Qin¹^ORCID

Affiliation:

1. Department of Gastroenterology, The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou China

Publisher

Wiley

Subject

Infectious Diseases,Gastroenterology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hel.12940

Reference36 articles.

1. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis

2. Prevalence of Helicobacter pylori infection in China: A systematic review and meta‐analysis

3. Gastric cancer

4. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population

5. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of Vonoprazan-based treatment of Helicobacter pylori infection: a systematic review and network meta-analysis;BMC Infectious Diseases;2024-09-11

2. Vonoprazan Dual or Triple Therapy Versus Bismuth‐Quadruple Therapy as First‐Line Therapy for Helicobacter pylori Infection: A Three‐Arm, Randomized Clinical Trial;Helicobacter;2024-09

3. Efficacy and safety of 10-day versus 14-day bismuth-containing quadruple therapy for H. pylori eradication: A systematic review and meta-analysis;2024-08-20

4. Efficacy and Safety of Vonoprazan-Based Quadruple Therapy for the Eradication of <i>Helicobacter pylori</i> in Patients with Peptic Ulcers: A Pooled Analysis of Two Randomized, Double-Blind, Double-Dummy, Phase 3 Trials;Biological and Pharmaceutical Bulletin;2024-08-01

5. Vonoprazan‐based therapies versus PPI‐based therapies in patients with H. pylori infection: Systematic review and meta‐analyses of randomized controlled trials;Helicobacter;2024-05